Novozymes and Chr. Hansen revealed the future name of their combined entity - 'Novonesis.'
Source: The DairyNews
On December 12, 2022, Novozymes and Chr. Hansen disclosed their intent to merge and establish a prominent global biosolutions partner through a statutory merger.
Subsequently, on March 30, 2023, shareholders of Novozymes and Chr. Hansen greenlit the proposed merger, paving the way for the creation of a leading global biosolutions entity. The finalization of this merger is contingent on customary merger control processes and regulatory clearances fr om pertinent authorities.
On December 13, the companies revealed the future name of their combined entity as 'Novonesis.' This name signifies the commencement of a biosolutions era wh ere Novonesis aims to unleash the complete potential of biological solutions, delivering substantial value to stakeholders and society as a whole. The announcement of the name stands as a significant milestone in the integration of the two entities.
Ester Baiget, President and CEO of Novozymes, expressed, "Novonesis reflects where we came from, what we can achieve, and what we will become together. We are dedicated to harness the transformative potential of biology." Baiget emphasized the commitment to uniting expertise and cutting-edge technology to address global challenges and initiate a new era of biosolutions.
Cees de Jong, Chairman of Novozymes, stated, "We believe we have found that name in Novonesis. A name that reflects our immense commitment to making biological solutions play an even bigger role in our planet’s future." The name 'Novonesis' is complemented by a brand identity inspired by the field of microbiology.
The merger approval process is advancing as scheduled, with the anticipated completion in the first quarter of 2024 following regulatory approval. The Novonesis name will be adopted gradually upon the completion of the proposed combination. Until the final approvals are secured, Novozymes and Chr. Hansen will continue to operate as distinct entities.
On December 13, the companies revealed the future name of their combined entity as 'Novonesis.' This name signifies the commencement of a biosolutions era wh ere Novonesis aims to unleash the complete potential of biological solutions, delivering substantial value to stakeholders and society as a whole. The announcement of the name stands as a significant milestone in the integration of the two entities.
Ester Baiget, President and CEO of Novozymes, expressed, "Novonesis reflects where we came from, what we can achieve, and what we will become together. We are dedicated to harness the transformative potential of biology." Baiget emphasized the commitment to uniting expertise and cutting-edge technology to address global challenges and initiate a new era of biosolutions.
Cees de Jong, Chairman of Novozymes, stated, "We believe we have found that name in Novonesis. A name that reflects our immense commitment to making biological solutions play an even bigger role in our planet’s future." The name 'Novonesis' is complemented by a brand identity inspired by the field of microbiology.
The merger approval process is advancing as scheduled, with the anticipated completion in the first quarter of 2024 following regulatory approval. The Novonesis name will be adopted gradually upon the completion of the proposed combination. Until the final approvals are secured, Novozymes and Chr. Hansen will continue to operate as distinct entities.
Key News of the Week
